AI
DNTH icon

Atria Investments’s Dianthus Therapeutics DNTH Stock Holding History

Atria Investments’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+2,171
New +$190K ﹤0.01% 2043
2020
Q1 		– Sell
-772
Closed -$187K – 695
2019
Q4 		$187K Buy
+772
New +$144K 0.01% 1160
2019
Q2 		– Sell
-737
Closed -$194K – 992
2019
Q1 		$194K Buy
+737
New +$127K 0.01% 876

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Atria Investments's DNTH Position: Q2 2026 in Review

Atria Investments opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 2,171 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #2043 among its holdings. This is a return to the name: Atria Investments previously reported a position in DNTH as recently as Q4 2019.

Atria Investments first reported a position in DNTH in Q1 2019 and has held it in 3 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Atria Investments held 2,171 shares of Dianthus Therapeutics worth $212K as of Q2 2026.
  • Dianthus Therapeutics was a new Atria Investments position in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #2043 holding.
  • Atria Investments first reported a position in Dianthus Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.